Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,965Revenue $M269Net Margin (%)-23.3Z-Score8.0
Enterprise Value $M3,625EPS $-0.5Operating Margin %-23.3F-Score3
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-23.3Higher ROA y-yY
Price/Book17.610-y EBITDA Growth Rate %-4.5Quick Ratio3.3Cash flow > EarningsY
Price/Sales14.15-y EBITDA Growth Rate %-16.3Current Ratio3.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-13.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-28.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M124ROI % (ttm)-20.8Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGENRay Dalio 2014-09-30 Buy $33.75 - $44.14
($39.36)
$ 32-19%New holding, 6140 sh.6,140
SGENRay Dalio 2014-06-30 Sold Out -0.01%$32.82 - $46.79
($37.8)
$ 32-15%Sold Out0
SGENRay Dalio 2014-03-31 Buy 0.01%$38.57 - $55.14
($47.61)
$ 32-33%New holding, 22400 sh.22,400
SGENPRIMECAP Management 2011-06-30 Add0.05%$15 - $21.34
($17.98)
$ 3278%Add 21.21%9,572,853
SGENPRIMECAP Management 2011-03-31 Add0.04%$13.95 - $17.23
($15.41)
$ 32108%Add 29.25%7,897,953
SGENPRIMECAP Management 2010-12-31 Add0.06%$13.77 - $17.35
($15.64)
$ 32105%Add 77.8%6,110,600
SGENPRIMECAP Management 2010-09-30 Buy 0.09%$11.44 - $15.08
($12.22)
$ 32162%New holding, 3436800 sh.3,436,800
SGENJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.34 - $12.59
($10.84)
$ 32195%Sold Out0
SGENJean-Marie Eveillard 2009-12-31 Buy 0.01%$8.74 - $13.16
($9.69)
$ 32230%New holding, 67373 sh.67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
($11.69)
$ 32174%Sold Out0
SGENJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$8.18 - $10.34
($9.08)
$ 32252%Sold Out0
SGENJean-Marie Eveillard 2009-03-31 Add$7.23 - $10.36
($9.4)
$ 32240%Add 40%70,000
SGENJean-Marie Eveillard 2008-12-31 Buy 0.01%$7.76 - $10.6
($8.9)
$ 32260%New holding, 50000 sh.50,000
SGENJean-Marie Eveillard 2008-09-30 Sold Out $8.23 - $12.97
($11)
$ 32191%Sold Out0
SGENJean-Marie Eveillard 2008-06-30 Buy $8.79 - $10.59
($9.6)
$ 32233%New holding, 60000 sh.60,000
SGENJean-Marie Eveillard 2007-06-30 Sold Out -0.01%$8.48 - $10.41
($9.7)
$ 32230%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SGEN Ray Dalio 2014-09-306,14000New Buy
SGEN PRIMECAP Management 2014-09-3010,954,9008.840.44+0.54%
Premium Most recent portfolio changes are included for Premium Members only!


SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BAKER FELIXDirector, 10% Owner 2014-12-16Buy2,883,378$31.860.44view
BAKER FELIXDirector, 10% Owner 2014-12-10Buy1,247,896$33.82-5.38view
FBB3 LLCDirector, 10% Owner 2014-12-09Sell0$0-5.38view
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci. 2014-11-12Sell10,000$37.52-14.71view
BAKER FELIXDirector, 10% Owner 2014-11-10Buy1,653,925$34.56-7.41view
SIEGALL CLAY BPresident and CEO 2014-09-04Sell5,600$42.54-24.78view
DOBMEIER ERICCOO 2014-08-25Sell4,818$43.55-26.52view
SIMPSON TODD ECFO 2014-08-24Sell3,696$43.55-26.52view
SIEGALL CLAY BPresident and CEO 2014-08-24Sell25,507$43.55-26.52view
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci. 2014-08-24Sell3,310$43.55-26.52view

Press Releases about SGEN :

    Quarterly/Annual Reports about SGEN:

      News about SGEN:

      Articles On GuruFocus.com
      Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
      Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
      Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
      Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
      Comment for Companies Ranked by Business Predictability Jan 03 2013 
      Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
      WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
      Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 
      5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
      Weekly CFO Sells Highlight: SGEN, APKT, AMRC, FNGN Oct 10 2011 

      More From Our Partners
      Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day Dec 19 2014 - ZACKS

      More From Other Websites
      Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of... Dec 18 2014
      Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin)... Dec 08 2014
      Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS(R) (Brentuximab... Dec 08 2014
      Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting Dec 08 2014
      Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at... Dec 08 2014
      Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting Dec 08 2014
      Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-cell Lymphoma at... Dec 08 2014
      Seattle Genetics CEO: Blockbuster cancer drug? Dec 08 2014
      Seattle Genetics-Takeda's Adcetris Shows Long-Term Effect Dec 08 2014
      Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in... Dec 08 2014
      Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in... Dec 08 2014
      Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab... Dec 08 2014
      Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin)... Dec 07 2014
      Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin)... Dec 07 2014
      Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin)... Dec 07 2014
      Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting Dec 06 2014
      Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting Dec 06 2014
      Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab... Dec 06 2014
      Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab... Dec 06 2014
      Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab... Dec 06 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK